Zydus and Torrent Pharma Partner to Co-Market Semaglutide Injection in India

Zydus Lifesciences Limited has entered into a licensing and supply agreement with Torrent Pharmaceuticals Limited to jointly market Semaglutide Injection in India. 

The collaboration aims to expand access to treatment options for patients with type 2 diabetes and weight-related conditions. The agreement combines manufacturing capabilities with market reach to improve availability across the country.

Details of the Licensing Agreement

Under the arrangement, Zydus will manufacture and supply the Semaglutide Injection, while Torrent Pharma has been granted semi-exclusive rights to co-market the product in India.

Torrent Pharma will introduce the drug under its own brand, while also paying an upfront licensing fee to Zydus as part of the agreement. The partnership is structured to leverage the strengths of both companies in production and distribution.

Product Development and Formulation

Zydus has developed a formulation of Semaglutide Injection (15 mg/3 ml) delivered through a prefilled cartridge. The product is administered using a reusable pen device designed for patient convenience.

This delivery mechanism enables multiple dosage strengths through a single platform, which may support improved treatment adherence and ease of use for patients managing chronic conditions.

Branding and Market Strategy

Zydus plans to market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™. Meanwhile, Torrent Pharma will distribute the same under the brand SEMBOLIC™.

This dual-branding approach allows both companies to utilise their respective market networks and therapeutic segment presence to reach a wider patient base.

Therapeutic Applications

Semaglutide is indicated for adults with type 2 diabetes mellitus, particularly where blood sugar levels are not adequately controlled through existing treatments. It may be used as a standalone therapy when certain medications are unsuitable or alongside other treatments.

Additionally, the drug is indicated for chronic weight management in adults with obesity or those who are overweight with associated health conditions such as hypertension or dyslipidaemia.

Strategic Objective of the Partnership

The collaboration brings together Zydus’s research, development and manufacturing expertise with Torrent Pharma’s established presence in chronic therapy segments.

The shared objective is to improve access to GLP-1 based therapies in India, addressing growing demand for treatments related to metabolic disorders.

Zydus Lifesciences Limited Share Price Performance

Shares of Zydus Lifesciences Limited showed a positive trend on March 18, 2026. The stock opened at ₹891.15 and moved between a low of ₹889.00 and a high of ₹905.95 during the session.

It was last recorded at ₹898.85, reflecting a gain of ₹8.70 or 0.98% compared to the previous close of ₹889.80. The indicative closing price stood at ₹899.90, suggesting steady market activity.

Read More:Andhra Cements Shares Rise After Sagar Cements Announces OFS Stake Sale.

Conclusion

The agreement between Zydus and Torrent Pharma represents a collaborative approach to expanding access to treatment for diabetes and weight management in India. By combining manufacturing, innovation and distribution capabilities, the partnership aims to address evolving healthcare needs while maintaining a focus on patient accessibility.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.